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Colorectal cancer (CRC) is one of the most common malignancies worldwide,
1,2
and the adenoma-carcinoma sequence is a well-established aspect of its carcino-
genesis.
3 In addition to adenoma-carcinoma related genes, much attention has
been focused on the involvement of cyclooxygenase (COX) in tumor develop-
ment and progression.
4 COX is a rate-limiting enzyme in the biosynthesis of pro-
staglandins from arachidonic acid, and exists in two well-characterized isoforms,
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Purpose: In addition to cyclooxygenase-2 (COX-2) which is related to prostaglan-
din E2 synthesis, other enzymes such as cytosolic phospholipase A2 (cPLA2),
microsomal prostaglandin E2 synthase-1 (mPGES-1), and 15-prostaglandin dehy-
drogenase (15-PGDH) have been suggested to be related to carcinogenesis of
colorectal cancer (CRC). The aim of this study was to investigate the roles of
cPLA2, COX-2, mPGES-1, and 15-PGDH in tumor progression. Materials and
Methods: cPLA2, COX-2, mPGES-1, 15-PGDH, and vascular endothelial growth
factor (VEGF) expressions were immunohistochemically examined in 89 CRC,
and their expressions were compared with each other or clinicopathologic parame-
ters as well as VEGF as tumor progression parameters. Results: cPLA2 was expr-
essed in 54.5%, COX-2 in 80.5%, mPGES-1 in 96.4%, 15-PGDH in 46.1%, and
VEGF in 65.9%. The expression of cPLA2 correlated with VEGF expression.
COX-2 expression was correlated with the depth of invasion, tumor stage, cPLA2,
and VEGF expressions. Moreover, VEGF revealed the highest expression in the
tissues positive for both cPLA2 and COX-2. Furthermore, 15-PGDH expression
was inversely correlated with VEGF expression. Conclusion: The present study
demonstrates that cPLA2 and mPGES-1, in addition to COX-2, are constitutively
overexpressed, and that 15-PGDH might be attenuated in colorectal cancer. Furt-
hermore, cPLA2 and 15-PGDH as well as COX-2 could have an important role in
tumor progression. 
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INTRODUCTIONi.e., COX-1 and COX-2. The former is constitutively ex-
pressed in a wide variety of tissues, where it serves a homeo-
static function. On the other hand, COX-2 is not expressed
under normal conditions, however, its expression is in-
duced in response to cytokines, growth factors, tumor pro-
moters, and others. Moreover, COX-2 expression has
pathophysiologically been associated with inflammation,
wound healing, and carcinogenesis. And high levels of
constitutive COX-2 expression have been reported in many
tumors, including those of the lung, breast, esophagus,
stomach, and especially, in CRC. Furthermore, it has been
suggested that COX-2 overexpression is associated with
tumor formation and growth, angiogenesis, and meta-
stasis.
5-7 However, the clinical impact of COX-2 overex-
pression on oncologic outcomes in CRC is unclear. Some
authors have concluded that COX-2 overexpression in
CRC is associated with poor survival,
8,9 whereas another
study and our previous study failed to demonstrate that
COX-2 overexpression in CRC is associated with a poor
prognosis.
10,11 Therefore, we hypothesized that COX-2-
related oncologic effect could be influenced by other factors.
In addition to being dependent on COX-2, prostaglandin
production is also directly dependent on the availability of
free arachidonic acid (AA), which is released from mem-
brane glycerophospholipid by the hydrolysis of fatty acid
from its sn-2 position by PLA2.
13 Several types of PLA2
are expressed in human cells, and 85 kDa IVA cytosolic
PLA2 (cPLA2) of these is the major intracellular form. Mo-
reover, cPLA2 is widely expressed and plays an essential
role in stimulus-induced AA release.
14,15 Because of its im-
portance in the generation of prostaglands (PGs), it has also
been suggested to participate in intestinal tumorigenesis. 
PGH2, which is synthesized by the action of COX-2, is
isomerized to PGE2 by terminal prostaglandin E synthase
(PGES), and multiple isoforms of terminal PGES have so
far been identified.
12,16 The cytosolic PGES (cPGES) is
constitutively expressed and functionally coupled to COX-
1,
17 whereas the microsomal prostaglandin E synthase-1
(mPGES-1) is rapidly induced by various stimuli in a
COX-2 expression-related manner.
12,16 The physiologic rele-
vance of mPGES-1 expression in vivo has been substan-
tiated recently by the finding that mPGES-1-deficient mice
display attenuated responses to inflammation and pain.
19
Furthermore, mPGES-1 is constitutively expressed in colon,
lung, and gastric cancers,
20-22 suggesting that it participates
in tumorigenesis. 
In addition, NAD
+-linked 15-PGDH is of central impor-
tance during the biological inactivations of prostaglan-
dins,
23 and recent studies suggested that 15-PGDH has a
tumor suppressing effect in several cancers.
24,25
Thus, we undertook the present study to determine the
effect of COX-2 and its coupled enzymes using human
colorectal carcinoma samples. In addition to clinicopathol-
ogic parameters such as TNM staging, differentiation, and
recurrence, we also evaluated VEGF expression, which is
known to be up-regulated in most human tumors, including
colorectal cancer, and has been associated with increased
invasiveness, recurrent disease, and a poor prognosis.
26 We
then compared VEGF expression (which was used in this
study as a tumor progression marker) with those of cPLA2,
COX-2, mPGES-1, and 15-PGDH to determine whether
these enzymes act as tumor promoters or suppressors. 
Patients and tissue samples
Eighty-nine patients who had undergone surgical resection
for primary sporadic colorectal carcinoma by a single
colorectal surgeon at the Department of Surgery, Chosun
University Hospital between March 2002 and December
2005 were included in this study. No patient had a history
of hereditary CRC syndrome or regularly used aspirin-like
drugs. Patients that received pre-operative chemotherapy
or radiotherapy were not included. Included patients were
followed up until death or August 2007; median post-
operative follow up duration was 38.01 ± 12.58 months.
Forty patients had colon cancer and 49 rectal cancer, and
mean patient age was 63.43 ± 12.63 years. Samples were
graded by pathologists according to the pathological fea-
tures of tumors, i.e., histologic grade, lymph node metas-
tasis, distant metastasis, and tumor stage (AJCC TNM
classification). In all cases, archived H&E stained tissue
slides were retrieved to confirm pathological features and
to select suitable tissue blocks for immunohistochemical
analysis.
Immunohistochemistry
A universal immunoenzyme polymer method was used for
immunostaining. Four-µm thick sections were cut from
formalin-fixed, paraffin-embedded tissue blocks, mounted
on poly-lysine-coated slides, dewaxed in xylene, and rehy-
drated through a graded ethanol series. After deparaffini-
zation, antigen retrieval treatment was performed at 121˚C
(autoclave) for 15 minutes in 10 mmol/L sodium citrate
buffer (pH 6.0), and sections were then treated with 3%
hydrogen peroxide in methanol solution for 20 minutes in
order to quench endogenous peroxidase activity. Nonspe-
cific bindings were blocked by treating slides with Ultra V
Block (UltraVision Plus Detection System, Thermo Scien-
tific, Fremont, CA, USA) and incubation for 5 minutes at
room temperature. The primary antibodies used were;
mouse monoclonal antibody to cPLA2 (1 : 100, 4˚C over-
night, Santa Cruz, CA, USA), mouse monoclonal antibody
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MATERIALS AND METHODSto COX-2 (1 : 400, 37˚C for one hour, Cayman, Ann Arbor,
MI, USA), mouse monoclonal antibody to mPGES-1 (1 :
200, 37˚C for one hour, Cayman), rabbit polyclonal anti-
body to 15-PGDH (1 : 2,000, 4˚C overnight, Novus Biologi-
cals, Littleton, CO, USA), and rabbit polyclonal antibody
to VEGF (1 : 100, 37˚C for one hour, Santa Cruz). Each
slide was washed four times in phosphate buffered saline
(PBS). Biotinylated goat anti-mouse or goat anti-rabbit
antibody (UltraVision Plus Detection System, Thermo
Scientific, Fremont, CA, USA) was applied and incubated
for 5 minutes at room temperature. Slides were washed
again four times in PBS. Streptavidin-Alkaline Phosphate
conjugate (UltraVision Plus Detection System) was then
applied and incubated for 5 minutes at room temperature.
Slides were washed four times in PBS. Fast Red/Naphtol
Phosphate substrate was applied to the sections for visuali-
zation and incubated for 10-20 minutes. Sections were
counterstained with Mayer’s hematoxylin for 20 sec before
air drying and coverslipping. Normal mouse serum IgG
(Vector Laboratories, Burlingame, CA, USA) was used in
place of the primary antibody as a negative control. Positive
control tissue was colon cancers and inflammatory cells
stained positively for VEGF, cPLA2, and mPGES-1.
Normal colonic epithelium was used as internal control for
PGDH. All experiments were performed in duplicate.
Immunohistochemical staining
Each slide was assessed by a pathologist who was unaware
of patient details. For cPLA2 and COX-2, the extent of
staining was graded as follows: 0 - staining in less than 1%
of tumor cells; 1 - staining in 1-20%; 2 - staining in 20-50%;
and 3 - staining in more than 50%. Overall intensity of stain-
ing was also assessed as follows: 0 no staining; 1 weak
staining; 2 moderate staining; and 3 strong staining. Final
scores (range from 0 to 9) were obtained by multiplying
staining extents and intensities. Final scores were describ-
ed as follows: 0, no expression; 1 to 3, weak expression; 4-
6, moderate expression; and 7-9, strong expression.
27 For
statistical analysis, no expression and weak expression
were combined and described as negative for expression,
and moderate and strong expression were combined and
described as positive for expression.
In the case of mPGES-1, percentages of tumor cells
showing cytoplasmic staining were scored as follows; mo-
derate to strong cytoplasmic positivity in > 10% of tumor
cells was regarded as positive, and faint cytoplasmic stain-
ing or moderate to strong cytoplasmic expression observed
in < 10% of tumor cells was regarded as negative.
28 For
15-PGDH, samples were defined as positive when ≥ 30%
of tumor cells were stained, and as negative when < 30%
of tumor cells were stained.
29 
Finally, VEGF staining was defined as positive when >
10% of tumor cells were stained, and as negative when ≤
10% of tumor cells were stained.
30 Representative exam-
ples of cPLA2, COX-2, mPGES-1, 15-PGDH, and VEGF
immunostained tumor tissue sections are shown in Fig. 1.
Sung Chul Lim, et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 5   September 2010 694
A B C
D E F
Fig.1. Immunohistochemical staining. (A) positive cPLA2 in tumor tissue. (B) Positive COX-2 in tumor tissue. (C) Positive mPGES-2 in tumor tissue.
(D) Positive 15-PGDH in normal colonic epithelium. (E) Negative 15-PGDH in tumor tissue. (F) Positive VEGF in tumor tissue. cPLA2, cytosolic
phospholipase A2; COX-2, cyclooxygenase 2; mPGES-2, microsomal prostaglandin E synthase-2; PGDH, prostaglandin dehydrogenase; VEGF,
vascular endothelial growth factor.Statistical analysis 
The χ 2 test and Fisher’s exact probability were used to
analyze the relationship of cPLA2, COX-2, mPGES-1 and
15-PGDH according to clinicopatologic parameters or
VEGF expression. Significance was defined as p values of
< 0.05. The SPSS version 12.0 software (SPSS Inc., Chi-
cago, IL, USA) package was used for statistical analysis.
Expression of cPLA2, COX-2, mPGES-1, and 
15-PGDH (Table 1)
cPLA2 staining was observed in the smooth muscle of the
muscularis propria and the muscularis mucosa, in some
superficial interstitial cells, and in rare endothelial cells. In
normal epithelial cells, there was no staining or weak
cPLA2 staining. COX-2 staining revealed negligible ex-
pression in normal epithelium, but districtly positive staining
in the interstitial cells, whereas mPGES-1 was not express-
ed in the adjacent normal mucosal epithelial cells. In normal
mucosa, 15-PGDH was seen in epithelial cells forming
villi (Fig. 1). 
cPLA2 expression was positive in 54.4% (48/88) of
tumor samples, COX-2 in 80.5% (66/82), mPGES-1 in
96.4% (81/84), and 15-PGDH in 46.1% (41/89). cPLA2
expression was significantly related to VEGF expression
(p = 0.016). Although cPLA2 expression was not signi-
ficantly related to clinicopathologic parameters such as
TNM staging, lymph node status, grade of differentiation,
and recurrence, cPLA2 expression tended to be high in
patients with an advanced stage or unfavorable clinico-
pathologic features such as pT3/pT4, positive lymph node
metastasis, elevated pre-operative CEA levels, and positive
recurrence. COX-2 expression was correlated with depth
of invasion (p = 0.002), TNM stage (p = 0.011), and VEGF
expression (p < 0.001). mPGES-1 was expressed in most
of the samples studied, however, its expression was not
found to be related to clinicopathologic parameters. 15-
PGDH expression was inversely correlated with VEGF
expression (p = 0.040). The expression of 15-PGDH was
high in patients with earlier stage disease or favorable
clinicopathologic features, such as well-differentiated can-
cer, normal pre-operative carcinoembryonic levels, and no
tumor recurrence. However, these relations were not stati-
stically significant.
Correlations between COX-2 expression and cPLA2 or 
15-PGDH expression
Seventy nine of total 89 cases were evaluated for both
COX-2 expression and cPLA2 expression. Comparing the
correlation of their expression with their staining scores,
COX-2 expression was positively correlated with cPLA2
expression (Fig. 2, p = 0.002), but not with 15-PGDH
expression (data not shown).
VEGF expression according to the status of cPLA2 and 
COX-2 
VEGF expression was positive in 65.9% of tissue samples,
but didn’t stain in the adjacent normal mucosal epithelium.
To clarify whether cPLA2 expression augments the onco-
genic effect of COX-2, we grouped the expression into 4
categories, i.e., group I, cPLA2 (-) and COX-2 (-); group II,
cPLA2 (+) and COX-2 (-); group III, cPLA2 (-) and COX-
2 (+); and group IV cPLA2 (+) and COX-2 (+). These
groups were then compared with the status of VEGF ex-
pression. VEGF expression was positive in 20.0% of group
I, in 33% of group II, in 61.5% of group III, and 83.3% in
group IV, showing the highest expression rate in both
cPLA2 and COX-2 positive cases. cPLA2 expression was
found to be a significant marker of VEGF expression in
addition to COX-2 expression (Table 2, p= 0.001). 
In the present study, we evaluated the expression profiles
of cPLA2, COX-2, mPGES-1, and 15-PGDH in patients
with colorectal cancer. The expressions of these entities are
known to be related closely to the synthesis and degrada-
tion of PGE2, which is known to be associated with resis-
tance to programmed cell death, cell migration, cell proli-
feration, and angiogenesis. However, there is so far no
study evaluating all these enzymes together. In the present
study, we demonstrated that cPLA2, COX-2, and mPGES-
1 were overexpressed in CRC tissues, and that cPLA2 and
COX-2 overexpressions were correlated with tumor pro-
gression. Furthermore, 15-PGDH expression was inversely
correlated with tumor progression. 
In this study, we found that COX-2 was overexpressed
in 80.5% of tissue samples tested, and that COX-2 expres-
sion was closely related to T-stage, TNM stage, and VEGF
expression status, suggesting that COX-2 participates in
tumor progression. These findings are in good agreement
with those of other studies.
8,9 In our previous studies, we
used a similar scoring system of COX-2, and found that
COX-2 was expressed in 42.4% to 47.8% of tumor tissues,
proven immunohistochemically,
11,31 which is quite different
from that found in the present result. However, the two
studies differ in terms of the secondary antibody kit used
(although the same primary antibody was used). 
It is unclear to what extent COX-2 overexpression in-
fluences tumor progression, or whether it has a prognostic
impact in CRC. A number of studies found that COX-2
cPLA2, 15-PGDH and COX-2 in Colorectal Cancer
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DISCUSSION
RESULTSexpression is a useful prognostic marker in CRC,
8,9 whereas
others, including our previous study, demonstrated that its
overexpression has little prognostic impact, although COX-
2 is aberrantly overexpressed in CRC.
10,11,32,33 Thus, the
present study was designed to identify whether or not the
enzymes involved in the metabolism of PGE2 affected
tumor progression.
Studies on the profiles and effects of cPLA2 expression
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Table 1.Correlation of Clinicopathologic Parameters with cPLA2, COX-2, mPGES-1, and 15-PGDH Expressions
Clinicopathologic 
cPLA2 (%) COX-2 (%) mPGES-1 (%) 15-PGDH (%)
parameters
All cases 48 / 88 (54.5) 66 / 82 (80.5) 81 / 84 (96.4) 41 / 89 (46.1)
Sex
Male 27 / 43 (62.8) 33 / 41 (80.5) 42 / 42 (100) 24 / 44 (54.5)
Female 21 / 45 (46.7) 33 / 41 (80.5) 39 / 42 (92.9) 17 / 45 (37.8)
Age
< 60 16 / 28 (57.1) 23 / 28 (82.1) 28 / 29 (96.6) 14 / 28 (50.0)
≥60 32 / 60 (53.3) 43 / 54 (79.6) 53 / 55 (96.4) 27 / 61 (44.3)
Site
Colon 23 / 38 (60.5) 29 / 36 (80.6) 35 / 36 (97.2) 19 / 40 (47.5)
Rectum 25 / 50 (50.0) 37 / 46 (80.4) 46 / 48 (95.8) 22 / 49 (44.9)
Depth of invasion
pT0 3 / 10 (30.0) 4 / 10 (40.0)
� 10 / 10 (100) 6 / 9 (66.7)
pT1 / pT2 11 / 24 (45.8) 19 / 24 (79.2) 19 / 21 (90.5) 11 / 23 (47.8)
pT3 / pT3 34 / 54 (63.0) 43 / 48 (89.6) 52 / 53 (98.1) 24 / 57 (42.1)
Lymph node metastasis
No 21 / 43 (48.8) 33 / 40 (82.5) 38 / 39 (97.4) 19 / 45 (42.2)
Yes 23 / 35 (65.7) 29 / 32 (90.6) 33 / 35 (94.3) 16 / 35 (45.7)
TNM stage
0 3 / 10 (30.0) 4 / 10 (40.0)
� 10 / 10 (100) 6 / 9 (66.7)
I 8 / 19 (42.1) 15 / 19 (78.9) 17 / 17 (100) 9 / 19 (47.4)
II 14 / 24 (58.3) 17 / 20 (85.0) 21 / 22 (95.5) 10 / 25 (40.0)
III 17 / 29 (58.6) 24 / 26 (92.3) 27 / 29 (93.1) 13 / 29 (44.8)
IV 6 / 6 (100) 6 / 7 (85.7) 6 / 6 (100) 3 / 7 (42.9)
Histologic differentiated
Well 10 / 14 (71.4) 12 / 15 (80.0) 15 / 16 (93.8) 9 / 16 (56.3)
Moderate / Poor 34 / 59 (57.6) 48 / 54 (88.9) 51 / 53 (96.2) 24 / 58 (41.4)
Pre-operative CEA level
Normal 23 / 49 (46.9) 35 / 46 (76.1) 45 / 47 (95.7) 25 / 50 (49.0)
Elevated  12 / 20 (60.0) 16 / 18 (88.9) 19 / 19 (100) 5 / 20 (25.0)
Recurrence
No 29 / 55 (52.7) 46 / 54 (85.5) 49 / 52 (94.2) 27 / 56 (48.2)
Yes 10 / 16 (62.5) 9 / 10 (90.0) 15 / 15 (100) 5 / 16 (31.3)
VEGF expression
Negative 11 / 30 (36.7)* 17 / 29 (58.6)
§ 27 / 29 (93.1) 18 / 30 (60.0)
‖
Positive   36 / 57 (63.2) 48 / 52 (92.3) 53 / 54 (98.1) 22 / 58 (37.9)
cPLA2, cytosolic phospholipase A2; COX-2, cyclooxygenase 2; mPGES-1, microsomal prostaglandin E 2 synthase-1; 15-PGDH, 15-prosta-
glandin dehydrogenase; CEA, carcinoembryonic antigen; VEGF, vascular endothelial growth factor.
*Negative VEGF expression vs. positive VEGF expression: p= 0.016.
�pT0 vs. pT1/pT2 vs. pT3/pT4: p= 0.002.
�TNM stage 0 vs. I vs. II vs. III vs. IV p= 0.011.
§ Negative VEGF expression vs. Positive VEGF expression: p< 0.001.
‖Negative VEGF expression vs. Positive VEGF expression: p= 0.040.in CRC have also revealed disparate results. In two animal
models of familial adenomatous polyposis, cPLA2 was
overexpressed in small bowel adenoma, but not in colonic
adenoma. Furthermore, cPLA2 knock-out mice were found
to have dramatically reduced small bowel polyp develop-
ment but not colonic polyp development, suggesting that
cPLA2 had an oncologic effect.
34,35 On the other hand,
cPLA2 expression was diminished in azoxymethane-
induced mouse colon tumors,
36 and knock-out of cPLA2
enhanced colon tumor development.
37 Moreover, available
results on cPLA2 expression in human colorectal adeno-
carcinoma have also been highly variable. Some have
suggested that cPLA2 is overexpressed,
38-40 whereas others
have concluded to the contrary.
36,41,42 However, the study
sample sizes were relatively small, i.e., ranging from 5 to
48. Panel, et al.
27 reported that cPLA2 was overexpressed
in 49% of 65 patients with colorectal cancers, and that
cPLA2 expression was correlated with COX-2 expression,
which concurs with our findings; i.e., we demonstrated that
cPLA2 was overexpressed in 54.5% of CRCs (n = 88), and
that cPLA2 expression was correlated with the expressions
of COX-2 and VEGF. Furthermore VEGF levels were
found to be significantly elevated when both cPLA2 and
COX-2 were expressed. These results strongly suggest that
cPLA2 plays an important role in tumor development
and/or progression in CRC, and that the expressions of
cPLA2 plus COX-2 might be a good marker of tumor pro-
gression and/or prognosis. 
Like COX-2, it has been reported that mPGES-1 is consti-
tutively overexpressed in many cancers, including colorec-
tal cancer.
21,22,28,43 Yoshimatsu, et al.
43 reported that mPGES-1
was overexpressed in more than 80% of human colorectal
cancers and adenomas. We also demonstrated that mPGES-1
was expressed in most invasive colorectal cancers and in
carcinoma in situ. It has been suggested that aberrant
mPGES-1 expression in combination with COX-2 expres-
sion could contribute to tumorigenesis in vitro.
20 And Naka-
nishi, et al.
44 reported that genetic deletion of mPGES-1
suppressed intestinal tumorigenesis, and suggested that
mPGES-1 could be a target for cancer chemoprevention
with the potential for improved tolerability over traditional
nonsteroidal anti-inflammatory drugs and selective COX-2
inhibitors. mPGES-1 is specifically involved in PGE2 syn-
thesis, but not in synthesis of other prostaglandins such as
PGI2 decrease of which is responsible for side effect of
long-term use of NSAID or COX-2 inhibitors. Furthermore,
mPGES-1 is constitutively overexpressed at all stages of
tumors. Therefore, it may be a attractive therapeutic target
in terms of chemoprevention and overcoming the short-
comings of COX-2 inhibitors. 
Most of the PGE2 synthesized by cPLA2, COX-2, and
mPGES-1 are degraded by 15-PGDH, which catalyzes the
NAD
+-dependent oxidation of the 15-OH group of prosta-
glandin to a 15-keto group.
23 Accordingly, 15-PGDH is a
normal physiologic antagonist of COX-2. Yan, et al.
45 found
that 15-PGDH mRNA and protein are highly expressed in
normal colonic epithelial tissues, but almost undetectable
in colon cancer tissues, and that the restoration of 15-PGDH
levels inhibit tumor formation in mice, thus providing
strong evidence that 15-PGDH could act as a tumor supp-
ressor during colon cancer development. However, the
expression of 15-PGDH in human cancer tissues has only
been studied in a small number of cancers and its expres-
sion has been found to vary widely. Yan, et al. reported
that 15-PGDH expression was immunohistochemically
negative in 16 of 17 colon cancer cases and in 10 of 13
gastric cancers. In one study using Northern and Western
blotting-based assay, 15-PGDH levels were lower in 85%
cPLA2, 15-PGDH and COX-2 in Colorectal Cancer
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Fig. 2. Relationship between COX-2 and cPLA2 expression in colorectal cancer
(n = 79, r = 0.339, p = 0.002). COX-2, cyclooxygenase 2; cPLA2, cytosolic
phospholipase A2. 
Table 2.VEGF Expression According to the Status of both cPLA2 and COX-2 (p= 0.001)
cPLA2 (-) cPLA2 (+) cPLA2 (-) cPLA2 (+)
COX-2 (-) COX-2 (-) COX-2 (+) COX-2 (+)
Positive for 2 / 10 2 / 6 16 / 26 30 / 36
VEGF (%) (20.0) (33.3) (61.5) (83.3)
cPLA2, cytosolic phospholipase A2; COX-2, cyclooxygenase 2; mPGES-1, microsomal prostaglandin E 2 synthase-1; 15-PGDH, 15- 
prostaglandin dehydrogenase; VEGF, vascular endothelial growth factor.of 23 pairs of colon carcinoma samples than in adjacent
normal mucosa,
24 and in another study using real time RT-
PCR study in breast cancer, 15-PGDH expression was
down-regulated in 64% (16 of 28) of tumors.
46 In addition,
one bladder cancer study found that 15-PGDH was expre-
ssed in 64% (18 of 28) of transitional cell carcinomas and
in 1 of 10 squamous cell carcinomas.
47 In contrast, how-
ever, Yoo, et al.
29 reported that 15-PGDH was immunohi-
stochemically expressed in 54 (90%) of 60 in gastric
cancer. In the present study, 15-PGDH was found to be
expressed in 46.1% (41 of 89) of colorectal cancers, and its
expression showed a trend of positive expression in pati-
ents with favorable clinicopathologic parameters, such as
pT0, well differentiated histologic pattern, normal pre-
operative carcinoembryonic antigen levels, and no recur-
rence (Table 1). Furthermore, we found that 15-PGDH
expression was not correlated with COX-2 expression, and
that its expression was significantly higher in tumor tissues
which did not express VEGF. Our results suggest that 15-
PGDH has tumor suppressive activity in colorectal cancer,
However, further large scaled studies are needed to clarify
the precise role of 15-PGDH played in tumor progression.
In conclusion, the present study demonstrates that
cPLA2 and mPGES-1, in addition to COX-2, are constitu-
tively overexpressed, and that 15-PGDH might be attenu-
ated in colorectal carcinoma. Furthermore, cPLA2 and 15-
PGDH as well as COX-2 could have an important role in
tumor progression. 
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